NURPF Stock Neuren Pharmaceuticals (NURPF, $12) RSI Indicator left the oversold zone on September 26, 2025

GET DAILY SIGNALS

Get AI intraday signals

NURPF - Neuren Pharmaceuticals Ltd.

RSI signal

View

Odds of UP Trend

Price: $12

Daily change: +$1.07 (+9.79%)

Daily volume: 150

Capitalization: $1.6B

Industry: Biotechnology

NURPF in upward trend: price may jump up because it broke its lower Bollinger Band on September 22, 2025

NURPF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 26 cases where NURPF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 02, 2025. You may want to consider a long position or call options on NURPF as a result. In of 62 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NURPF just turned positive on October 02, 2025. Looking at past instances where NURPF's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

NURPF moved above its 50-day moving average on September 26, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NURPF advanced for three days, in of 28 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NURPF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NURPF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.913) is normal, around the industry mean (24.376). P/E Ratio (19.952) is within average values for comparable stocks, (54.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.175). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (13.624) is also within normal values, averaging (341.418).